Merck’s anti-PD-1 therapy, Keytruda, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency.
Merck’s anti-PD-1 therapy, Keytruda, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of patients with PD-L1-positive esophageal squamous cell carcinoma who have progressed after chemotherapy and for a six-week dosing schedule across all adult indications.
According to an Aug. 24, 2020 press release, these latest approvals means that Keytruda now has 13 indications across seven tumor types plus MSI-H tumors in Japan. The approval for use in patients with esophageal squamous cell carcinoma has been based on results from the global Phase III KEYNOTE-181 trial. For the six-week dosing schedule, the approval has been based on pharmacokinetic modeling and exposure-response analyses.
“We remain committed to improving outcomes for as many patients with cancer as possible, including those with esophageal squamous cell carcinoma, which is a leading cause of cancer-related death in Japan,” said Dr. Jonathan Cheng, vice president, oncology clinical research, Merck Research Laboratories, in the press release. “With today’s approvals, specific patients with esophageal cancer can receive a much-needed new treatment option, and adult patients receiving Keytruda will now have the option of a dosing schedule that reduces how often they are at the clinic for treatment.”
Source: Merck
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.